Virax Biolabs Group (NASDAQ:VRAX) Shares Down 11.3% – Should You Sell?

Virax Biolabs Group Limited (NASDAQ:VRAX) was down 11.3% during mid-day trading on Tuesday . The stock traded as low as $0.4516 and last traded at $0.4692. Approximately 1,125,054 shares traded hands during mid-day trading, a decline of 93% from the average daily volume of 15,278,406 shares. The stock had previously closed at $0.5291.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Virax Biolabs Group in a report on Tuesday, October 14th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $3.00.

Virax Biolabs Group Stock Down 11.3%

The stock’s fifty day moving average price is $0.54 and its 200 day moving average price is $0.71.

Virax Biolabs Group (NASDAQ:VRAX) last released its earnings results on Tuesday, December 2nd. The company reported ($0.27) EPS for the quarter. The company had revenue of $0.00 million during the quarter.

Virax Biolabs Group Company Profile

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.